Get the Stockscreener App
41.32
2.62%
-1.12
Qiagen Nv stock is traded at $41.32, with a volume of 664.18K.
It is down -2.62% in the last 24 hours and down -10.59% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
See More
Previous Close:
$42.44
Open:
$41.38
24h Volume:
664.18K
Relative Volume:
0.71
Market Cap:
$9.17B
Revenue:
$1.97B
Net Income/Loss:
$92.93M
P/E Ratio:
101.62
EPS:
0.4066
Net Cash Flow:
$459.60M
1W Performance:
-7.41%
1M Performance:
-10.59%
6M Performance:
-9.60%
1Y Performance:
-7.67%
1-Day Range:
$40.85
$41.48
1-Week Range:
$40.85
$44.20
52-Week Range:
$40.15
$49.30
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
41.33 | 9.17B | 1.97B | 92.93M | 459.60M | 0.4066 |
|
TMO
Thermo Fisher Scientific Inc
|
572.57 | 219.06B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
207.63 | 151.02B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
145.71 | 42.12B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
459.86 | 37.71B | 3.84B | 866.24M | 792.60M | 10.37 |
|
IQV
Iqvia Holdings Inc
|
207.83 | 36.97B | 15.32B | 1.41B | 1.96B | 7.62 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
Qiagen N.V. (NYSE:QGEN) Q4 2024 Earnings Call Transcript - Insider Monkey
QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand - Yahoo Finance
Qiagen Exceeds 2024 Financial Outlook with Solid Growth - TipRanks
Qiagen (NYSE:QGEN) Receives $50.07 Consensus Price Target from Brokerages - MarketBeat
QIAGEN Reports Solid Growth and Exceeds 2024 Outlook - TipRanks
Qiagen targets 4% CER sales growth for 2025 with key portfolio advancements - MSN
Qiagen N.V. Q4 2024 Earnings Call: Strong Growth Amid Challenges - TipRanks
Wellington Management Group LLP Increases Stake in Qiagen NV - GuruFocus.com
Qiagen: Q4 Earnings Snapshot - The Washington Post
Qiagen N : QIAGEN delivers solid Q4 2024 growth ahead of outlook -February 06, 2025 at 01:04 am EST - Marketscreener.com
Qiagen (QGEN) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Qiagen (QGEN) Q4 Earnings Lag Estimates - Yahoo Finance
Qiagen Earnings Review: Q4 Summary - Benzinga
Qiagen Q4 Earnings Report: What Investors Need to Know - Benzinga
QIAGEN delivers solid Q4 2024 growth ahead of outlook - Business Wire
Qiagen NV (QGEN) Q4 2024 Earnings Report Preview: What To Expect - GuruFocus.com
Qiagen Gets Patent Reaffirmation From German Court -February 04, 2025 at 05:50 pm EST - Marketscreener.com
QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patent - DutchNews.nl
Short Interest in Qiagen (NYSE:QGEN) Drops By 18.0% - MarketBeat
Qiagen Announces Managerial Share Consolidation Following Repurchase Plan - TipRanks
Exchange Traded Concepts LLC Has $776,000 Holdings in Qiagen (NYSE:QGEN) - MarketBeat
Qiagen (QGEN) Expected to Announce Earnings on Wednesday - MarketBeat
Fifth Third Bancorp Reduces Stake in Qiagen (NYSE:QGEN) - MarketBeat
QIAGEN Implements Share Consolidation in Strategic Move - TipRanks
QIAGEN N.V. Announces Share Consolidation as Part of Strategic Financial Plan - TipRanks
QIAGEN Announces Manager’s Share Consolidation - TipRanks
QIAGEN’s Share Consolidation Impacts Managerial Holdings - TipRanks
QIAGEN Announces Share Consolidation under Synthetic Repurchase Plan - TipRanks
QIAGEN N.V. Executes Share Consolidation Following Synthetic Repurchase Approval - TipRanks
QIAGEN Announces Synthetic Share Repurchase Impacting Managerial Holdings - TipRanks
Is QIAGEN Stock an Apt Pick for Your Portfolio Right Now? - Yahoo Finance
[Latest] Global Single Cell Multiomics Market Size/Share Worth USD 18.90 Billion by 2033 at a 19.58% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) - GlobeNewswire Inc.
Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Qiagen N : VENLO -January 29, 2025 at 06:08 am EST - Marketscreener.com
Qiagen’s Institutional Investment Spotlight: BlackRock’s Voting Rights Revealed - TipRanks
Qiagen Insiders Sell US$7.0m Of Stock, Possibly Signalling Caution - Simply Wall St
REVERSE SPLIT WITH CHANGE OF ISIN AND SHORT CODE PLUS DIVIDEND: QIAGEN NV - Wiener Börse
RNA Editing Market Top Companies StudyQIAGEN N.V., UniquQuire - openPR
Park Avenue Securities LLC Buys 2,166 Shares of Qiagen (NYSE:QGEN) - Defense World
Qiagen (NYSE:QGEN) Shares Bought by Assenagon Asset Management S.A. - Defense World
SG Americas Securities LLC Reduces Holdings in Qiagen (NYSE:QGEN) - MarketBeat
Crossmark Global Holdings Inc. Sells 18,306 Shares of Qiagen (NYSE:QGEN) - MarketBeat
Qiagen stock hits 52-week high at $47.45 amid steady growth - Investing.com Australia
Qiagen (NYSE:QGEN) Sets New 52-Week HighTime to Buy? - MarketBeat
Genetic Testing Market Projected To Witness Substantial Growth, 2025-2032: Eurofins Scientific, Illumina Inc., - EIN News
QGEN Stock Might Rise Following Partnership With Genomics England - MSN
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.49%
2.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):